Horizon Discovery Group plc Presentation at 2019 Cowen Health Care Conference

TIDMHZD

Horizon Discovery Group plc

11 March 2019

Horizon Discovery Group plc

Horizon Discovery to Present at the 2019 Cowen Health Care Conference

Cambridge, UK, 11 March 2019: Horizon Discovery Group plc (LSE: HZD) ("Horizon" or "the Group" or "Company"), a global leader in the application of gene editing and gene modulation technologies, today announces that Terry Pizzie, Horizon's Chief Executive Officer, will provide an overview and company update, and host meetings with investors at the 39(th) Annual Cowen Health Care Conference.

Details of the presentation are as follows:

 
Date:        Tuesday, March 12, 2019 
Time:        11.20-11.50 a.m. EDT (15.20-15.50p.m. GMT) 
Location:    Nantucket Room, 4th Floor. Boston Marriott Copley Place, 
              Boston 
 

A live webcast of the presentation will be available to watch here, and an archived replay accessible after the conference for 90 days.

Investors interested in arranging a meeting with the Company's management, team during this conference should contact the conference coordinator, or email [e-mail].

ENDS

For further information from Horizon Discovery Group plc, please contact:

Horizon Discovery Group plc

Terry Pizzie, Chief Executive Officer

Tel: [phone]

Numis Securities Limited (Broker and NOMAD)

Michael Meade / Freddie Barnfield / Duncan Monteith

Tel: [phone]

Consilium Strategic Communications (Financial Media and Investor Relations)

Mary-Jane Elliott / Matthew Neal / Melissa Gardiner

Tel: [phone]

Email: [e-mail]

About Horizon Discovery Group plc www.horizondiscovery.com

Horizon Discovery Group plc (LSE: HZD) ("Horizon") is a world leader in gene editing and gene modulation technologies. Horizon designs and engineers cells using its translational genomics platform, a highly precise and flexible suite of DNA editing tools (rAAV, ZFN, CRISPR, Transposon and base editing) and, following the acquisition of Dharmacon, Inc., its functional genomics platform comprising gene knockdown (RNAi) and gene expression (cDNA, ORF) tools, for research and clinical applications that advance human health. Horizon's platforms and capabilities enable researchers to alter almost any gene or modulate its function in human or mammalian cell-lines.

Horizon offers an extensive range of catalogue products and related research services to support a greater understanding of the function of genes across all species and the genetic drivers of human disease and the development of personalised molecular, cell and gene therapies. These have been adopted by over 10,000 academic, drug discovery, drug manufacturing and clinical diagnostics customers around the globe, as well as in the Company's own R&D pipeline.

Horizon is headquartered in Cambridge, UK, and is listed on the London Stock Exchange's AIM market under the ticker HZD

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [e-mail] or visit www.rns.com.

END

NRAGGUMWWUPBPUU

(END) Dow Jones Newswires

March 11, 2019 03:01 ET (07:01 GMT)